NCT02021162View on ClinicalTrials.gov

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

October 31, 2018

Conditions
Multiple SclerosisHealthy
Trial Locations (1)

14203

Buffalo Neuroimaging Analysis Center, Buffalo

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University at Buffalo

OTHER